Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 16:31 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Leuprolide Acetate or Goserelin Acetate With or Without Vismodegib Followed by Surgery in Treating Patients With Locally Advanced Prostate Cancer
NCT01163084 · National Cancer Institute (NCI) · PHASE1/PHASE2 · terminated · last registry update 2019-02-28 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
No reason was published
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | The registry record gives no reason | – | Registry record, National Cancer Institute (NCI) |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against GNRHR within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2020-01-21Results posted on the registry: Astellas Pharma Global Development, Inc., Enzalutamide + Placebo (NCT02677896)
- 2019-12-09Phase 3 first posted: Merck Sharp & Dohme LLC, Pembrolizumab + Enzalutamide (NCT04191096)
- 2019-12-09Results posted on the registry: University of Colorado, Denver, leuprolide acetate + Estradiol Transdermal (NCT00687739)
- 2019-11-29Phase 3 first posted: UNICANCER, Apalutamide + Luteinising Hormone Releasing Hormone agonist (LHRHa) (NCT04181203)
- 2019-11-21Phase 3 first posted: Yale University, Elagolix 200 MG (NCT04173169)
- 2019-11-08Phase 3 first posted: UNICANCER, Paclitaxel injection + Capecitabine tablets (NCT04158362)
- 2019-10-23Phase 3 first posted: University of Sydney, Darolutamide + Placebo oral tablet (NCT04136353)
- 2019-09-03Phase 3 first posted: Astellas (Beijing) Pharmaceutical R&D Co., Ltd., Enzalutamide + Placebo (NCT04076059)
- 2019-08-22Phase 3 first posted: The University of Hong Kong, IVF: Decapeptyl and hCG + FET: Decapeptyl (NCT04064840)
- 2019-05-29Results posted on the registry: ETOP IBCSG Partners Foundation, triptorelin + degarelix (NCT02005887)
- 2019-05-03Phase 3 first posted: Eurofarma Laboratorios S.A., Inj. Goserelin (Test) Subcutaneously + Inj. Zoladex (Reference) Subcutaneously (NCT03936218)
- 2019-05-03Phase 3 first posted: Eurofarma Laboratorios S.A., Goserelin acetate 3.6 mg Injection + ZOLADEX® 3.6mg Injection (NCT03936933)
- 2019-01-29Phase 3 first posted: ETOP IBCSG Partners Foundation, Palbociclib 125mg + Standard endocrine therapy (NCT03820830)
- 2018-12-06Phase 3 first posted: Janssen Research & Development, LLC, Apalutamide + Androgen Deprivation Therapy (ADT) (NCT03767244)
- 2018-10-10Phase 3 first posted: Novartis Pharmaceuticals, Ribociclib (NCT03701334)
- 2018-09-19Phase 3 first posted: SWOG Cancer Research Network, Abiraterone + Bicalutamide (NCT03678025)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision